ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Paxlovid. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2023-02-01

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.

Ranganath N, O'Horo JC, Challener DW, Tulledge-Scheitel SM, Pike ML, O'Brien M, Razonable RR, Shah A.

Clin Infect Dis · brief-report; journal article · DOI 10.1093/cid/ciac481

Bibliografisk träff 2023-02-01

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.

Carlin AF, Clark AE, Chaillon A, Garretson AF, Bray W, Porrachia M, Santos AT, Rana TM, Smith DM.

Clin Infect Dis · brief-report; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/ciac496

Bibliografisk träff 2023-02-01

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).

Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Turbett SE, Li JZ, Lemieux JE, Barczak AK, Siedner MJ.

Clin Infect Dis · brief-report; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/ciac512

Bibliografisk träff 2023-01-01

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.

Saravolatz LD, Depcinski S, Sharma M.

Clin Infect Dis · research-article; review; journal article · DOI 10.1093/cid/ciac180

Bibliografisk träff 2022-07-06

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.

Larsen CS.

Int J Infect Dis · brief-report; journal article · DOI 10.1016/j.ijid.2022.06.059

Bibliografisk träff 2022-07-05

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.

Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M, Chan PLS, Demers N, Corrigan B, Damle B.

Clin Pharmacol Ther · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1002/cpt.2688

Bibliografisk träff 2022-07-04

Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.

Wang Z, Chan ECY.

Clin Pharmacol Ther · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1002/cpt.2687

Bibliografisk träff 2022-07-02

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation.

Antonelli G, Focosi D, Turriziani O, Tuccori M, Brandi R, Fillo S, Ajassa C, Lista F, Mastroianni CM.

Clin Microbiol Infect · letter · DOI 10.1016/j.cmi.2022.06.029

Bibliografisk träff 2022-07-01

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.

Ross SB, Bortolussi-Courval É, Hanula R, Lee TC, Goodwin Wilson M, McDonald EG.

JAMA Netw Open · research-article; journal article · DOI 10.1001/jamanetworkopen.2022.20184

Bibliografisk träff 2022-06-28

Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression.

Mecadon K, Arvanitis P, Farmakiotis D, Rogers R.

Clin Transplant · letter · DOI 10.1111/ctr.14752

Bibliografisk träff 2022-06-24

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SY.

MMWR Morb Mortal Wkly Rep · journal article · DOI 10.15585/mmwr.mm7125e2

Bibliografisk träff 2022-06-17

COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.

Coulson JM, Adams A, Gray LA, Evans A.

J Infect · letter · DOI 10.1016/j.jinf.2022.06.011

Bibliografisk träff 2022-06-09

Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD.

Hiremath S, McGuinty M, Argyropoulos C, Brimble KS, Brown PA, Chagla Z, Cooper R, Hoar S, Juurlink D, Treleaven D, Walsh M, Yeung A, Blake P.

Clin J Am Soc Nephrol · research-article; journal article · DOI 10.2215/cjn.05270522

Bibliografisk träff 2022-06-07

Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S.

Clin Pharmacol Ther · review-article; review; journal article · DOI 10.1002/cpt.2646

Bibliografisk träff 2022-06-07

In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.

Vassilopoulos A, Mylonakis E.

Ann Intern Med · comment; journal article · DOI 10.7326/j22-0038

Bibliografisk träff 2022-06-01

Correction to: Nirmatrelvir Plus Ritonavir: First Approval.

Lamb YN.

Drugs · published erratum; correction · DOI 10.1007/s40265-022-01737-9

Bibliografisk träff 2022-06-01

Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19.

Lindauer KE, Hamel AG.

Am Fam Physician · letter; case reports

Bibliografisk träff 2022-06-01

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study.

Yan G, Zhou J, Zhu H, Chen Y, Lu Y, Zhang T, Yu H, Wang L, Xu H, Wang Z, Zhou W.

Ann Transl Med · research-article; journal article · DOI 10.21037/atm-22-2791

Bibliografisk träff 2022-05-23

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns.

Sánchez Fabra D, Herrero Jordán T.

Enferm Infecc Microbiol Clin · journal article; case reports; case-report · DOI 10.1016/j.eimc.2022.04.007

Bibliografisk träff 2022-05-01

Nirmatrelvir/Ritonavir Reduces Risk of Hospitalization in At-Risk Outpatients.

Ebell MH.

Am Fam Physician · journal article

Bibliografisk träff 2022-04-20

Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).

Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E, SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group, SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group.

Therapie · research-article; journal article · DOI 10.1016/j.therap.2022.03.005

Bibliografisk träff 2022-04-06

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.

Hong E, Almond LM, Chung PS, Rao AP, Beringer PM.

Clin Pharmacol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cpt.2585

Bibliografisk träff 2022-04-01

Nirmatrelvir Plus Ritonavir: First Approval.

Lamb YN.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-022-01692-5

Bibliografisk träff 2022-03-21

Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.

Salerno DM, Jennings DL, Lange NW, Kovac DB, Shertel T, Chen JK, Hedvat J, Scheffert J, Brown RS, Pereira MR.

Am J Transplant · brief-report; journal article · DOI 10.1111/ajt.17027

Bibliografisk träff 2022-03-07

Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.

S K SR, P A A, B S, Kalala KP, Pm A, Sabarathinam S.

Diabetes Metab Syndr · review-article; review; journal article · DOI 10.1016/j.dsx.2022.102451

Bibliografisk träff 2022-03-01

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.

Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back D, Khoo S.

Ann Intern Med · other; research support, non-u.s. gov't; editorial · DOI 10.7326/m22-0281

Bibliografisk träff 2022-02-28

Nirmatrelvir and ritonavir for COVID-19.

Författaruppgift saknas

Aust Prescr · review-article; review; journal article · DOI 10.18773/austprescr.2022.015

Bibliografisk träff 2022-02-09

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Hung YP, Lee JC, Chiu CW, Lee CC, Tsai PJ, Hsu IL, Ko WC.

Antibiotics (Basel) · other; journal article · DOI 10.3390/antibiotics11020220

Bibliografisk träff 2022-02-03

Nirmatrelvir-ritonavir for COVID-19.

McDonald EG, Lee TC.

CMAJ · comment; other; research support, non-u.s. gov't; journal article · DOI 10.1503/cmaj.220081